Cathepsin cysteine protease inhibitors

US9573913B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Shawn J. Stachel · Perkasie, US
• Daniel V. Paone · Lansdale, US
• Jing Li · Lansdale, US
• Anthony Ginnetti · Perkasie, US
• John Lim · Perkiomenville, US
• Jianmin Fu · Beijing, CN
• Shimin Xu · Beijing, CN

Key dates

• Filing date: Oct 3, 2014
• Grant date: Feb 21, 2017
• Expiry date: Oct 3, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.